Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies
- PMID: 15852444
- DOI: 10.1002/gps.1341
Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies
Abstract
Introduction: Behavioural symptoms are common in moderate to severe Alzheimer's disease (AD). We have analysed the databases of two randomised studies with regard to the effects of memantine treatment on behavioural symptoms, measured using the 12-item version of the Neuropsychiatric Inventory (NPI).
Subjects: The monotherapy study (memantine only) reported by Reisberg et al. (2003) involved 252 patients with baseline MMSE total score of between 3 and 14, whereas the combination study (memantine and donepezil) reported by Tariot et al. (2004) comprised 404 patients with MMSE scores of between 5 and 14. In both studies, patients received 10 mg memantine b.i.d. or matching placebo, and lived in the community.
Methods: For both studies NPI total and individual domains scores were analysed in the ITT population. For the monotherapy study a dichotomised analysis was performed separately for patients who had behavioural symptoms at baseline and for those without pre-existing symptoms. Furthermore, a factor analysis was used to identify any behavioural clusters within the patient population.
Results: In both studies, the change in NPI total scores at endpoint was consistently in favour of memantine treatment, reaching statistical significance in the combination study (p = 0.002). Memantine treatment showed a significant beneficial effect in comparison to placebo treatment in the NPI agitation/aggression domain in both studies (p = 0.008; p = 0.001). The dichotomised analysis of the monotherapy study showed that there was significantly less agitation/aggression emerging in the memantine-treated group compared to placebo (p = 0.003). Factor analysis showed that hyperactivity accounted for 27% of the data variance.
Conclusions: Memantine has a beneficial effect on the behavioural symptoms of patients with moderate to severe AD, with the most pronounced effect on agitation/aggression.
Copyright 2005 John Wiley & Sons, Ltd.
Similar articles
-
Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.Int J Geriatr Psychiatry. 2009 May;24(5):532-8. doi: 10.1002/gps.2226. Int J Geriatr Psychiatry. 2009. PMID: 19274640
-
Efficacy of memantine on behavioral and psychological symptoms related to dementia: a systematic meta-analysis.Ann Pharmacother. 2008 Jan;42(1):32-8. doi: 10.1345/aph.1K372. Epub 2007 Dec 4. Ann Pharmacother. 2008. PMID: 18056833
-
Memantine therapy of behavioral symptoms in community-dwelling patients with moderate to severe Alzheimer's disease.Dement Geriatr Cogn Disord. 2009;27(2):164-72. doi: 10.1159/000200013. Epub 2009 Feb 5. Dement Geriatr Cogn Disord. 2009. PMID: 19194105 Review.
-
Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.Dement Geriatr Cogn Disord. 2007;24(2):138-45. doi: 10.1159/000105162. Epub 2007 Jul 4. Dement Geriatr Cogn Disord. 2007. PMID: 17622761
-
Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.Alzheimer Dis Assoc Disord. 2006 Jan-Mar;20(1):23-9. doi: 10.1097/01.wad.0000201847.29836.a5. Alzheimer Dis Assoc Disord. 2006. PMID: 16493232 Review.
Cited by
-
Memantine treatment for neuropsychiatric symptoms in a patient with probable idiopathic normal pressure hydrocephalus: a case report.J Med Case Rep. 2013 Apr 5;7:94. doi: 10.1186/1752-1947-7-94. J Med Case Rep. 2013. PMID: 23561702 Free PMC article.
-
Diagnosis and treatment of dementia: 6. Management of severe Alzheimer disease.CMAJ. 2008 Dec 2;179(12):1279-87. doi: 10.1503/cmaj.070804. CMAJ. 2008. PMID: 19047609 Free PMC article. Review.
-
Efficacy and safety of memantine in patients with moderate-to-severe Alzheimer's disease: results of a pooled analysis of two randomized, double-blind, placebo-controlled trials in Japan.Expert Opin Pharmacother. 2014 May;15(7):913-25. doi: 10.1517/14656566.2014.902446. Epub 2014 Mar 27. Expert Opin Pharmacother. 2014. PMID: 24673497 Free PMC article. Clinical Trial.
-
New approaches to the treatment of frontotemporal lobar degeneration.Curr Opin Neurol. 2008 Dec;21(6):708-16. doi: 10.1097/WCO.0b013e328318444d. Curr Opin Neurol. 2008. PMID: 18989117 Free PMC article. Review.
-
The efficacy of licensed-indication use of donepezil and memantine monotherapies for treating behavioural and psychological symptoms of dementia in patients with Alzheimer's disease: systematic review and meta-analysis.Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):212-27. doi: 10.1159/000330032. Epub 2011 Jul 20. Dement Geriatr Cogn Dis Extra. 2011. PMID: 22163246 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical